RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

Core Insights - RenovoRx has appointed Dr. Thierry de Baère, a leading expert in interventional oncology, to its Scientific Advisory Board, enhancing its expertise in targeted drug-delivery and locoregional cancer therapies [1][5]. Company Overview - RenovoRx, Inc. is a life sciences company focused on developing innovative targeted oncology therapies and commercializing RenovoCath, an FDA-cleared drug-delivery device [6]. - The company's Trans-Arterial Micro-Perfusion (TAMP™) therapy platform aims to optimize targeted drug delivery while minimizing toxicities compared to systemic intravenous therapy [6]. Expertise and Contributions - Dr. de Baère is the Head of the Interventional Radiology Unit at Gustave Roussy Cancer Centre and has extensive experience in minimally invasive therapies for various cancers [3][4]. - He has over 400 peer-reviewed publications and has received numerous awards, including the 2019 CIRSE Gold Medal [4]. Clinical Development - RenovoRx is evaluating a novel drug-device combination product candidate, intra-arterial gemcitabine delivered via RenovoCath (IAG), in the ongoing Phase III TIGeR-PaC trial [7]. - IAG has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which grants seven years of market exclusivity upon FDA approval [8]. Commercialization Efforts - The company is actively commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath devices [9]. - Several customers have initiated repeat orders, indicating growing demand, particularly from National Cancer Institute-designated centers [9].